From 4ab5804052d60e206399072a16ae5a89d446e213 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 16:00:36 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index 1f9631d1..41dacae3 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -17,7 +17,8 @@ - Qualification at EMA for art. 58 - Safety of IVM up to 600μg/kg alone and in coformulation with albendazole - Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa - - FDC of ivm/alb has the lowe + - FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016) + - - Investigadores principales de cada uno de los partners - Timeline y milestones (cuáles se han cumplido?) - __Proposed safety and effectiveness study__